A72 MECHANISMS DRIVING FIBROSIS: Safety And Efficacy Of Allogeneic Lung Spheroid Cells In A Mismatched Rat Model Of Pulmonary Fibrosis

Rationale: Idiopathic pulmonary fibrosis is a devastating interstitial lung disease characterized by deposition of extracellular matrix causing lung distortions and dysfunctions. Methods: Six to eight-week-old female Wistar Kyoto (WKY) or Brown Norway (BN) rats were randomized into 4 treatment groups. (a) WKY Control (Bleo + saline): intratracheal instillation of 1.5 U/kg body weight bleomycin in 250 ^l of PBS, followed by tail vein injection of 300 ^l PBS after 24 hours; (b) BN Control (Bleo + saline): intratracheal instillation of 1.5 U/kg body weight bleomycin in 250 ^l of PBS, followed by tail vein injection of 300 ^l PBS after 24 hours; (c) WKY syngeneic therapy (Bleo + synLSC): intratracheal instillation of 1.5 U/kg body weight bleomycin in 250 ^l of PBS, followed by tail vein injection of 5 x 106 WKY LSCs in 300 ul PBS after 24 hours. (d) BN allogeneic therapy (Bleo + alloLSC): intratracheal instillation of 1.5 U/kg body weight bleomycin in 250 ^l of PBS, followed by tail vein injection of 5 x 106 WKY LSCs in 300 ^l PBS after 24 hours.